Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type ii diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'- dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline

Journal of Medicinal Chemistry

Volumn 42, Issue 9, 1999, Pages 1587-1603

  Le Bihan, Gaëlle ^a   Rondu, Frédéric ^a   Pelé Tounian, Agnès ^b   Wang, Xuan ^a,b   Lidy, Sandrine ^a   Touboul, Estéra ^a   Lamouri, Aazdine ^a   Dive, Georges ^f   Huet, Jack ^a   Pfeiffer, Bruno ^c   Renard, Pierre ^c   Guardiola Lemaître, Béatrice ^d   Manéchez, Dominique ^d   Pénicaud, Luc ^e   Ktorza, Alain ^b   Godfroid, Jean Jacques ^a  

^a Laboratoire de Pharmacochimie   (France)

^b EUROPEAN SPACE AGENCY   (France)

^c ADIR   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIISOPROPYL 2 (4',5' DIHYDRO 1'H IMIDAZOL 2'YL)PIPERAZINE; 2 METHYLIMIDAZOLINE; AMIDINE; ANTIDIABETIC AGENT; DIISOBUTYL 2 (4',5' DIHYDRO 1' H IMIDAZO 2' YL)PIPERAZINE; IMIDAZOLINE DERIVATIVE; OXAZOLINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TETRAHYDROPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HYPOGLYCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; CATTLE; CEREBRAL CORTEX; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INJECTIONS, INTRAPERITONEAL; INSULIN; KIDNEY CORTEX; MALE; PIPERAZINES; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033529046     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981099b     Document Type: Article

References (44)

1. + Channel in Insulin-Secreting Cells. J. Biol. Chem. 1987, 262, 15840-15844.
2. Bailey, C. J.; Nattrass, M. Treatment - Metformin. Bailiere's Clin. Endocrinol. Metab. 1988, 2, 455-476.
3. Jackson, R. A.; Mawa, M. I.; Jaspan, J. B.; Sim, B. M.; Di Silvio, L.; Featherbe, D.; Kurtz, A. B. Mechanisms of Metformin Action in Non-Insulin-Dependent Diabetes. Diabetes 1987, 36, 632-640.
4. Hermann, L. S.; Melander, A. Biguanides: Basic aspects and clinical uses. In International Textbook of Diabetes Mellitus; Alberti, K. G. M. M., De Fronzo, R. A., Keen, H., Zimmet, P., Eds.; John Wiley & Sons Ltd.: New York, 1992; pp 773-795.
5. Campbell, I. W. In Sulphonylureas and Metformin: Efficacy and Inadequacy in New Antidiabetic Drugs; Bailey, C. J., Flatt, P. R., Eds.; Smith-Gordon: London, 1990; pp 33-51.
6. Berger, W. Incidence des effets secondaires sévères sous traitement par des sulfonylurées et des biguanides. Journée de Diabétologie Hôtel-Dieu; Flammarion: Paris, 1986; pp 243-253.
7. Kameda, K.; Ono, S.; Aboko, Y. Hypoglycemic Action of 2-[2-(4′,5′-Dihydro-1′H-imidazol-2′-yl)]-1- phenylethylpyridme dihydrochloride Sesquihydrate (DG-5128), a New Hypoglycaemic Agent. Arzneim. Forsch. Drug Res. 1982, 32, 39-44.
8. 2-Adrenergic Blocker (DG-5128) improves Insulin Secretion and in vivo Glucose Disposal in NIDDM Patients. Diabetes 1986, 35, 1085-1089.
9. Use of Pyrrolo [3,2,1-hi] indole Derivatives in the Manufacture of a Medicament for the Treatment of Diabetes. EP 0311467; Synthelabo.
10. Annu. Drug Data Rep. 1992, 995.
11. + Channels in Pancreatic B-cells. Eur. J. Pharmacol. 1994, 264, 81-84.
12. Berritge, T. L.; Doxey, J. C.; Roach, A. G. Comparison of the Effects of Efaroxan and Glibenclamide on Plasma Glucose and Insulin Levels in Rats. Eur. J. Pharmacol. 1992, 213, 213-218.
13. Östenson, C. G.; Cattaneo, A. G.; Doxey, J. C.; Efendic, S. Alpha-Adrenoceptors and Insulin Release from Pancreatic Islets of Normal and Diabetic Rats. Am. J. Physiol. 1989, 257, E439-E443.
14. Chan, S. L. F. Role of Alpha-2 Adrenoceptors and Imidazoline-Binding Sites in the Control of Insulin Secretion. Clin. Sci. 1993, 85, 671-677.
15. Schultz, A.; Hasselblatt, A. An Insulin-Releasing Property of Imidazoline Derivatives is not limited to Compounds that block α-Adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989, 340, 321-327.
16. Rondu, F.; Le Bihan, G.; Wang, X.; Lamouri, A.; Touboul, E.; Dive, G.; Bellahsene, T.; Pfeiffer, B.; Renard, P.; Guardiola-Lemaître, B.; Manéchez, D.; Penicaud, L.; Ktorza, A.; Godfroid, J.-J. Design and Synthesis of Imidazoline Derivatives Active on Glucose Homeostasis in a Rat model of Type II Diabetes. 1. Sybthesis and Biological Activity of N-benzyl-N′-alkyl-2-(4′,5′-dihydro-1′#-imidazol- 2′-yl)piperazines. J. Med. Chem. 1997, 40, 3793-3803.
17. Wang, X.; Rondu, F.; Lamouri, A.; Dokhan, R.; Touboul, E.; Pfeiffer, B.; Manéchez, D.; Renard, P.; Guardiola-Lemaître, B.; Godfroid, J.-J.; Ktorza, A.; Pénicaud, L. Effects of S-21663 (PMS 812), an Imidazoline Derivative, on Glucose Tolerance and Insulin Secretion in Rat Model of Type II Diabetes. J. Pharmacol. Exp. Ther. 1996, 278, 82-89
18. Le Brigand, L.; Virsolvy, A.; Peyrollier, K.; Manéchez, D.; Godfroid, J.-J.; Guardiola-Lemaître, B.; Bataille, D. Stimulation of Insulin Release from the MIN6 Cell Line by a New Imidazoline Compound S-21663 (PMS 812). Evidence for the Existence of a Novel Imidazoline Site in β Cells. Br. J. Pharmacol. 1997, 122, 786-791.
19. 1A Receptor Site. J. Med. Chem. 1992, 35, 2369-2374.
20. Clarke, H. T.; Gillespie, H. B.; Weisshans, S. Z. The Action of Formaldehyde on Amines and Amino acids. J. Am. Chem. Soc. 1933, 55, 4571-4587.
21. Le Bihan, G. Synthèses et études structure activité d'hétérocycles azotés actifs sur le diabète noninsulino dépendant. Ph.D. Thesis, University of Paris 5-René Descartes, 1997. The thesis is available in French librairies (microfilm). The results will be published elsewhere.
22. Neef, G.; Eder, U.; Sauer, G. One Step Conversions of Esters to 2-Imidazolines, Benzimidazoles and Benzothiazoles by Aluminium Organic Reagents. J. Org. Chem. 1981, 46, 2824-2826.
23. Aebischer, B.; Frey, P.; Haerter, H. P.; Herrling, P. L.; Mueller, W.; Olverman, H. J.; Watkins, J. C. Synthesis and NMDA Antagonistic Properties of the Enantiomers of 4-(3-Phosphonopropyl)piperazine-2-carboxylic acid (CPP) and Insaturated Analogue (E)-4-(3-Phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPP-ene). Helv. Chim. Acta 1989, 72, 1043-1051.
24. Garigipati, S. An Efficient Conversion of Nitriles to Amidines. Tetrahedron Lett. 1990, 31, 1969-1972.
25. Levin, J. I.; Turos, E.; Weinreb, S. M. An Alternative Procedure for the Aluminium-mediated Conversion of Esters to Amides. Synth. Commun. 1982, 12, 989-993.
26. Ramachandra, G. N.; Kattige, S. L.; Bhat, S. V.; Alreja, B.; De Sousa, N. J.; Rupp, R. H. An Antiinflammatory Cum Immuno-modulatory Piperidinylbenzopyranone: Isolation, Structure and Total Synthesis. Tetrahedron 1988, 44, 2081-2086.
27. Rothenberg, A. S.; Dauplaise, D. L.; Panser, H. P. A Simple Route to 2-Vinyl-imidazole. Angew. Chem., Int. Ed. Engl. 1983, 22, 560-561.
28. Thibault, C.; Laury, M. C.; Bailbe, D.; Ktorza, A.; Portha, B. Effect of Prolonged in vivo Glucose Infusion on Insulin Secretion in Rats with Previous Glucose Intolerance. Endocrinology 1992, 130, 2521-2527.
29. Chan, S. L. F.; Brown, C. A.; Morgan, N. G. Stimulation of Insulin Secretion by the Imidazoline alpha-2 Adrenoceptor Antagonist Efaroxan is Mediated by a Novel, Stereoselective, Binding Site. Eur. J. Pharmacol. 1993, 250, 375-378.
30. Pelé-Tounian, A.; Wang, X.; Rondu, F.; Lamouri, A.; Touboul, E.; Marc, S.; Dokhan, R.; Pfeiffer, B.; Manéchez, D.; Renard, P.; Guardiola-Lemaître, B.; Godfroid, J.-J.; Pénicaud, L.; Ktorza, A. Potent Antihyperglyceamic Property of a New Imidazoline Derivative S-22068 (PMS 847) in a Rat Model NIDDM. Br. J. Pharmacol. 1998, 124, 1591-1596.
31. 2-Sites. Proc. 2nd Int. Symp. Imidazoline Receptors 1994, P3.
32. +/ATP Channels in Insulin-secreting Cells. Eur. J. Pharmacol. 1991, 204, 41-48.
33. Chan, S. L. F.; Hurst, R. D.; Morgan, N. G. Effects of alpha-2 Adrenergic Antagonists on Insulin Secretion from Rat Pancreatic Islets. Biochem. Soc. Trans. 1988, 16, 1005-1006.
34. Chan, S. L. F.; Morgan, N. G. Stimulation of Insulin Secretion by Efaroxan may Involve Interaction with Potassium Channels. Eur. J. Pharmacol. 1990, 176, 97-101.
35. Chan, S. L. F.; Stillings, M. R.; Morgan, N. G. Mechanisms involved in Stimulation of Insulin Secretion by the Hypoglycemic alpha-Adrenergic Antagonist,DG-5128. Biochem. Biophys. Res. Commun. 1991, 176, 1545-1551.
36. 2 Receptors. Eur. J. Pharmacol. 1994, 262, 41-48.
37. Brown, C. A.; Lowett, A. C.; Smith, S. A.; Morgan, N. G. Stimulation of Insulin Secretion by Imidazoline Compounds is not due to Interaction with non-Adrenoceptor Idazoxan Binding Sites. Br. J. Pharmacol 1993, 108, 312-317.
38. 2-type Receptors. Pharmacological Characterization and Relationship to Monoamme Oxidase. Br. J. Pharmacol 1993, 109, 625-631.
39. Several publications are in preparation in this field concerning other molecules which are structurally different from this series. They will be submitted to J. Med. Chem.
40. Rekker, R. F.; De Koort, M. M. The Hydrophobic Fragmental Constant; Extension to a 1000 Data Points Set. Eur. J. Med. Chem. Chim. Ther. 1979, 14, 479-488.
41. Exploring QSAR. Hydrophobic, Electronic and Steric Constants; Hansch, C., Leo, A., Hoekman, D., Eds.; ACS Professionnal Reference Book; American Chemical Society: Washington, DC, 1995.
42. Coupry, I.; Podevin, R. A.; Dausse, J. P.; Parini, A. Evidence for Imidazoline Binding Sites in Basolateral Membranes from Rabbit Kidney. Biochem. Biophys. Res. Commun. 1987, 147, 1055-1060.
43. Reis, D. J.; Reunathan, S.; Meeley, P. M. P. Imidazoline Receptors and Clonidine-displacing Substance: Implication in Regulation of Arterial Pressure, Neuroprotection and Medulloadrenal Secretion. Am. J. Hyper. 1992, 5, 45S-46S.
44. 3H]RX821002 Radioligand Binding: Computer Modelling reveals that Guanfacine is an alpha-2A Selective Compound. Eur. J. Pharmacol. 1991, 202, 235-243.